OTCMKTS:IDRSF Idorsia (IDRSF) Stock Price, News & Analysis $4.70 0.00 (0.00%) As of 11/17/2026 Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartNews and Trends About Idorsia Stock (OTCMKTS:IDRSF) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Idorsia alerts:Sign Up Key Stats Today's Range$4.70▼$4.7050-Day Range$4.70▼$6.1552-Week Range$3.50▼$8.19VolumeN/AAverage Volume9,090 shsMarket CapitalizationN/AP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingModerate Buy Company Overview Idorsia Ltd. is a Swiss biopharmaceutical company focused on discovering, developing and commercializing medicines for diseases with significant unmet medical needs. Its research activities span areas including cardiovascular disease, central nervous system disorders, immunology and rare diseases. The company operates from its headquarters in Allschwil, Switzerland, and serves international pharmaceutical markets through its own commercial operations and collaboration arrangements. Idorsia’s commercial portfolio includes QUVIVIQ (daridorexant), an orexin receptor antagonist used to treat insomnia in eligible adults, and PIVLAZ (clazosentan), a therapy intended to reduce the risk of cerebral vasospasm and related complications following aneurysmal subarachnoid hemorrhage. The company has also developed aprocitentan, marketed as TRYVIO in the United States for certain adults with treatment-resistant hypertension. Idorsia was established in 2017 following the acquisition of Actelion by Johnson & Johnson, with Actelion’s discovery and early-stage research operations forming the foundation of the new company. Idorsia was founded by Jean-Paul Clozel and Martine Clozel and is led by Jean-Paul Clozel, who has served as chief executive officer. The company continues to advance a pipeline of internally discovered medicines alongside its marketed products.AI Generated. May Contain Errors. Read More Receive IDRSF Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Idorsia and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. IDRSF Stock News HeadlinesIdorsia Ltd (IDRSF) Shareholder/Analyst Call TranscriptNovember 8, 2026 | seekingalpha.comIdorsia Q3 Loss Narrows As Revenue Rises; Proposes CHF120 Mln Hypertension Drug PartnershipOctober 30, 2026 | rttnews.comYou missed yesterday's deadline…In June 2025, a drilling crew near the Grand Canyon uncovered an energy source producing nearly eight times the output of Saudi Arabia's largest oil well, enough potential energy to power civilization for two million years. While the One Big Beautiful Bill Act stripped tax credits from solar, wind, and EVs on July 4th, this discovery was reclassified alongside oil and nuclear and secured eight years of credits. Google signed a 15-year contract, and Bill Gates committed 100 million dollars.November 19 at 1:00 AM | Behind the Markets (Ad)Idorsia and SPV investors partner to unlock the blockbuster potential of TRYVIO/JERAYGO with a targeted launch in specialistsOctober 29, 2026 | marketscreener.comMIdorsia Proposes CHF120 Million Funding Deal with SPV Noteholders for Tryvio, Jeraygo LaunchOctober 29, 2026 | marketscreener.comMIdorsia Ltd Reports Earnings Results for the Nine Months Ended September 30, 2026October 29, 2026 | marketscreener.comMIdorsia Starts Phase 3 Fabry Disease Trial, Signs Nxera Deal For LucerastatOctober 28, 2026 | rttnews.comNxera Pharma Co., Ltd. Enters into Licensing and Commercialization Agreement with Idorsia Ltd for Lucerastat in Japan, South Korea, Taiwan and Selected Asia Pacific MarketsOctober 28, 2026 | marketscreener.comMSee More Headlines IDRSF Stock Analysis - Frequently Asked Questions How have IDRSF shares performed this year? Idorsia's stock was trading at $5.25 on January 1st, 2026. Since then, IDRSF stock has decreased by 10.5% and is now trading at $4.70. How do I buy shares of Idorsia? Shares of IDRSF stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Idorsia own? Based on aggregate information from My MarketBeat watchlists, some other companies that Idorsia investors own include Lakefront Biotherapeutics American Depositary Shares (LKFT), Moderna (MRNA), Tesla (TSLA), Workhorse Group (WKHS), Transocean (RIG), Air Canada (AC) and adidas (ADS). Industry, Sector and Symbol Stock ExchangeOTCMKTS SectorHealthcare Industry Biotechnology Sub-IndustryBiotechnology Current SymbolOTCMKTS:IDRSF CIKN/A Webwww.idorsia.com Phone(158) 844-0000FaxN/AEmployees487Year FoundedN/AProfitability EPS (Trailing Twelve Months)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current RatioN/A Quick RatioN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book ValueN/A Price / BookN/AMiscellaneous Outstanding SharesN/AFree FloatN/AMarket CapN/A OptionableNot Optionable BetaN/A The Best Nuclear Energy Stocks to BuyNuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.Get This Free Report This page (OTCMKTS:IDRSF) was last updated on 11/17/2026 by MarketBeat.com Staff. From Our PartnersTop Trader Reveals Stunning Black Friday DealOthers paid $500 for the Snapback Indicator. This Black Friday, it's available for just $7. Base Camp Tradi...Base Camp Trading | SponsoredToday's free pick (on me)Elon Musk doesn't own the chip inside every Tesla, Starlink dish, and AI satellite - he licenses it from one l...Behind the Markets | SponsoredYour free book is about to disappearBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredBeyond NVDA: The World’s Next #1 Company?This small-cap trades in an overlooked corner of the market, with a market cap more than 600X smaller than Nvi...Banyan Hill Publishing | SponsoredCFA: Bank of America Said THISOn January 24th, 2022, Bank of America told Bloomberg something that should terrify every American with a savi...Decentralized Masters | SponsoredMy public warning after 55 years of watching the marketsDr. Martin D. Weiss has publicly predicted six major American market crashes over his 55-year career, each war...Weiss Ratings | SponsoredThe investigation Porter spent tens of thousands to documentPorter Stansberry flew the Porter and Co. team 3,300 miles to Dublin to investigate a 17-year investing experi...Porter & Company | SponsoredThe next convergence is hereIn 2006, a flooded mine at Cigar Lake sent uranium prices from the $50 range to $136 in eight months. This pa...Digest Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Idorsia Ltd Please log in to your account or sign up in order to add this asset to your watchlist. Share Idorsia With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.